Alpha Cognition Inc (TSE:ACOG) has released an update.
Alpha Cognition Inc., a biopharmaceutical company, has achieved a significant milestone with the FDA approval of ZUNVEYL, a new therapy for Alzheimer’s disease designed to address tolerability issues and provide long-term efficacy. The company is gearing up for the commercial launch of the oral treatment, which marks the second such therapy approved this decade. Alpha Cognition is also progressing with pre-clinical studies and plans to target the Long-Term Care market, where there is a substantial opportunity and existing dissatisfaction with current treatments.
For further insights into TSE:ACOG stock, check out TipRanks’ Stock Analysis page.
